FDA Approves Generic Lanreotide, Challenging Somatuline Depot Market
The latest in this situation
How it started
What happened
The U.S. Food and Drug Administration approved a generic lanreotide injection for immediate launch, referencing Somatuline Depot. This generic was designated as a Competitive Generic Therapy and is used to treat acromegaly, advanced gastro-enteropancreatic neuroendocrine tumors, and carcinoid syndrome. The reference drug, Somatuline Depot, generated $983 million in annual U.S. sales for the year ended July 2026.
Why it matters
The approval introduces a new competitor to a specialty injectable market that previously generated nearly a billion dollars in U.S. brand sales. This increased generic competition could pressure domestic pricing and market share in regions like India.
From medicaldaily.com
Who's involved
- FDARegulatory agency that approved the generic lanreotide injection.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- IndiaSpeculative
Might face pressure on domestic pricing and market share due to increased generic competition in the specialty injectable market.
How it developed
Newest first. Tap a step to see who reported it.- The FDA approved the product launch of lanreotide.Sub-event
Generic approvals lead to market competition as Lanreotide challenges Somatuline Depot.1 source